Table 3 Activity of uveitis during etanercept and infliximab treatment at the end of the follow‐up compared with the baseline in 45 patients with juvenile idiopathic arthritis.

Response of uveitis	Etanercept	Infliximab	Total
Treatment failure, n (%)	13 (54.2)	4 (19)	17 (37.8)
No change, n (%)	6 (25)	8 (38.1)	14 (31.1)
Improved activity, n (%)	5 (20.8)	9 (42.9)	14 (31.1)